Brief: Ovid Therapeutics Reports Q3 Financial Results, Corporate Highlights

Ovid Therapeutics

08/11/2022 13:58

Nov 8 (Reuters) - Ovid Therapeutics Inc  OVID.O :
    * OVID THERAPEUTICS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS
AND CORPORATE HIGHLIGHTS
    * QTRLY LOSS PER SHARE $0.17
    * Q3 LOSS PER SHARE $0.17
    * ENDED QUARTER WITH CASH, CASH EQUIVALENTS, MARKETABLE
SECURITIES
$137.9 MILLION
    * QUARTER END CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES
EXPECTED TO SUPPORT ADVANCEMENT OF OVID'S EPILEPSY PIPELINE INTO
2025
    * Q3 EARNINGS PER SHARE VIEW $-0.21 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX6dyvK1 
Further company coverage:  OVID.O